Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Abstract Background PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects with biomarker-proven Alzheimer’s disease (AD). The aim was to determine...

Full description

Bibliographic Details
Main Authors: Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Charlotte E Teunissen, Alle Meije Wink, Paul Maruff, John Harrison, Caroline M van Baal, Suzanne Bruins, Inge Lues, Niels D Prins
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Glutaminyl cyclase inhibitor
PQ912
Phase 2a
Online Access:http://link.springer.com/article/10.1186/s13195-018-0431-6

Internet

http://link.springer.com/article/10.1186/s13195-018-0431-6

Similar Items